Clinical efficacy evaluation report of entacapone/cordan

Entacapone is an important auxiliary method in the treatment of Parkinson's disease. It mainly inhibits COMT and prolongs the action time of levodopa, thereby improving motor symptoms and "end-of-dose phenomenon". Core indicators for clinical efficacy evaluation include extension of patients' daily "on time" and "off time", reduction in movement fluctuations, and improvement in overall quality of life.

Clinical studies have shown that compared with levodopa alone, patients treated with entacapone have a significant increase in daily effective exercise time, and at the same time "off-period" symptoms are significantly reduced. This is particularly important for patients taking levodopa long-term, as monotherapy is prone to end-of-dose phenomena and motor fluctuations as the disease progresses. By coadministering entacapone, levodopa plasma concentrations can be more stable, thereby reducing diurnal symptom fluctuations and the occurrence of involuntary movements.

Effectiveness evaluation is not limited to motor symptoms, but also involves improvements in non-motor symptoms. For example, some patients reported reduced fatigue, improved ability to take care of themselves, and improved sleep quality after using entacapone. Overseas guidelines suggest that in clinical practice, patient self-rating scales, physician evaluation scales and daily life function assessments should be used comprehensively to comprehensively evaluate the efficacy. The purpose of efficacy evaluation is to provide a basis for individualized dose adjustment while ensuring that the drug maintains optimal therapeutic effect during long-term use.

In short, the efficacy of entacapone in the adjuvant treatment of Parkinson's disease has been widely recognized. Its main advantages are to prolong effective exercise time, reduce end-dose symptom fluctuations, and improve patients' quality of life. Clinical efficacy evaluation emphasizes dynamic monitoring and comprehensive indicator analysis to provide patients with scientific long-term medication management plans.

Reference materials:https://www.drugs.com/mtm/comtan.html